Nathan Weinstein
Stock Analyst at Aegis Capital
(0.28)
# 4,049
Out of 4,784 analysts
61
Total ratings
13.33%
Success rate
-26.12%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $1.31 | +6,006.87% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $20 → $15 | $0.62 | +2,307.70% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.55 | +990.91% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $1.20 | +2,816.67% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $1.80 | +233.33% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.21 | +1,257.47% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $6.50 | +53.85% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $15.95 | +207.21% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $5,250 → $150 | $1.47 | +10,104.08% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $4.35 | +49,555.17% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.13 | +2,554.87% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $0.69 | +1,357.73% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $22.39 | +614.60% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $20.33 | +175.45% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $1.47 | +1,736.73% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $1.00 | +3,400.00% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.75 | +585.71% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $10.22 | +633.86% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.58 | +1,790.68% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $2.59 | +6,849.81% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $9 | $0.44 | +1,959.50% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.01 | +179.44% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $0.44 | +2,398.86% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $2.97 | +186.20% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.31
Upside: +6,006.87%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $20 → $15
Current: $0.62
Upside: +2,307.70%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.55
Upside: +990.91%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $1.20
Upside: +2,816.67%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $1.80
Upside: +233.33%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.21
Upside: +1,257.47%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $6.50
Upside: +53.85%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $15.95
Upside: +207.21%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $5,250 → $150
Current: $1.47
Upside: +10,104.08%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $4.35
Upside: +49,555.17%
Dec 7, 2021
Initiates: Buy
Price Target: $30
Current: $1.13
Upside: +2,554.87%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $0.69
Upside: +1,357.73%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $22.39
Upside: +614.60%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $20.33
Upside: +175.45%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $1.47
Upside: +1,736.73%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $1.00
Upside: +3,400.00%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $1.75
Upside: +585.71%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $10.22
Upside: +633.86%
Oct 19, 2020
Maintains: Buy
Price Target: $13 → $11
Current: $0.58
Upside: +1,790.68%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $2.59
Upside: +6,849.81%
Aug 3, 2020
Maintains: Buy
Price Target: $13 → $9
Current: $0.44
Upside: +1,959.50%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $5.01
Upside: +179.44%
May 4, 2020
Maintains: Buy
Price Target: $9 → $11
Current: $0.44
Upside: +2,398.86%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $2.97
Upside: +186.20%